While Verona Pharma Plc ADR has underperformed by -4.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VRNA rose by 308.94%, with highs and lows ranging from $70.40 to $11.39, whereas the simple moving average jumped by 74.77% in the last 200 days.
On January 10, 2025, ROTH MKM started tracking Verona Pharma Plc ADR (NASDAQ: VRNA) recommending Buy. A report published by Wells Fargo on October 03, 2024, Initiated its previous ‘Overweight’ rating for VRNA. Jefferies also rated VRNA shares as ‘Buy’, setting a target price of $38 on the company’s shares in an initiating report dated May 22, 2023. Wedbush Initiated an Outperform rating on September 19, 2022, and assigned a price target of $27. Piper Sandler initiated its ‘Overweight’ rating for VRNA, as published in its report on August 26, 2022. H.C. Wainwright’s report from September 13, 2021 suggests a price prediction of $25 for VRNA shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Verona Pharma Plc ADR (VRNA)
One of the most important indicators of Verona Pharma Plc ADR’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -76.51% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and VRNA is recording 1.43M average volume. On a monthly basis, the volatility of the stock is set at 6.02%, whereas on a weekly basis, it is put at 6.63%, with a gain of 1.36% over the past seven days. Furthermore, long-term investors anticipate a median target price of $80.33, showing growth from the present price of $63.55, which can serve as yet another indication of whether VRNA is worth investing in or should be passed over.
How Do You Analyze Verona Pharma Plc ADR Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.31%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 69.61% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VRNA shares are owned by institutional investors to the tune of 69.61% at present.
